Dr. Reddy`s Laboratories gains on launching Saxagliptin and Metformin Hydrochloride Extended-Release Tablets
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Dr. Reddy's Laboratories is currently trading at Rs. 5849.65, up by 8.05 points or 0.14% from its previous closing of Rs. 5841.60 on the BSE.
The scrip opened at Rs. 5830.90 and has touched a high and low of Rs. 5881.05 and Rs. 5821.90 respectively. So far 3829 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 5916.85 on 10-Aug-2023 and a 52 week low of Rs. 3996.10 on 19-Sep-2022.
Last one week high and low of the scrip stood at Rs. 5916.85 and Rs. 5620.65 respectively. The current market cap of the company is Rs. 97717.53 crore.
The promoters holding in the company stood at 26.69%, while Institutions and Non-Institutions held 48.98% and 11.78% respectively.
Dr. Reddy's Laboratories has launched Saxagliptin and Metformin Hydrochloride Extended-Release Tablets in the U.S. market, a therapeutic equivalent generic version of KOMBIGLYZE XR (saxagliptin and metformin hydrochloride extended release) tablets, approved by U. S. Food and Drug Administration (USFDA).
Dr. Reddy’s Saxagliptin and Metformin Hydrochloride Extended-Release Tablets are supplied in a strength of 2.5 mg/1000 mg in bottle count of 60 and strengths of 5 mg/500 mg and 5 mg/1000 mg each in bottle counts of 30.
Dr. Reddy's Laboratories is a multinational pharmaceutical company based in Hyderabad, Telangana in India. It manufactures and markets a wide range of pharmaceuticals in India and overseas.
.jpg)
